Skip to content
Screener

Royalty Pharma RPRX Pre-Tax Income

Pre-Tax Income at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$64.3M+473%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.66M+1.3%
ALN
Alnylam PharmaceuticalsALNY
$177.81M+603%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$113.38M-192%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.09B+130%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$91M+20.2%

Other financials

Income statement

See full
Revenue$674.1M+16.5%
Operating income$133.1M-36.5%
Net income$17.9M-44.4%
EPS (diluted)$0.04-42.9%

Balance sheet

See full
Cash & equivalents$812.0M+28.5%
Total debt$9.0B+11.7%
Total equity$9.8B+3.1%
Total assets$19.8B+8.2%

Cash flow

See full
Operating cash flow$728.5M+100%

Valuation

See full
Market cap$25.38B+62.3%
Enterprise value$33.53B+45.6%
P/E31.1×+15.9×
P/S10×+3.2×

Profitability

See full
Operating margin59.6%-20.2pp
Net margin32.1%-12.3pp

Returns & leverage

See full
Return on equity8.5%-2.2pp
Debt / equity0.9×+0.1×
Current ratio2.8×+1.5×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:02 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001802768-26-000015
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Interest income(5,127)(8,327)(11,356)(19,617)
Other non-operating expenses, net1,4961,5433,6974,604
Total other expense, net51,633117,164146,415216,912
Consolidated net income before tax81,48692,635549,741527,068
Income tax expense
Consolidated net income81,48692,635549,741527,068
Net income attributable to non-controlling interests63,60360,459237,169255,543
Net income attributable to Royalty Pharma plc$17,883$32,176$312,572$271,525

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Royalty Pharma's pre-tax income?
Royalty Pharma (RPRX) reported pre-tax income of $81.49M in Q2 2026.
How has Royalty Pharma's pre-tax income changed year-over-year?
Royalty Pharma's pre-tax income decreased by 12.0% year-over-year, from $92.64M to $81.49M.
What is the long-term trend for Royalty Pharma's pre-tax income?
Over 3 years (2021 to 2025), Royalty Pharma's pre-tax income has grown at a 2.3% compound annual growth rate (CAGR), from $1.24B to $1.33B.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Royalty Pharma's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude